| 陆晓玲,李宗菊,吴晨,等.补肺益肾方对慢性阻塞性肺疾病稳定期患者肺康复的疗效观察[J].浙江中医药大学学报,2025,49(2):179-184, 196. |
| 补肺益肾方对慢性阻塞性肺疾病稳定期患者肺康复的疗效观察 |
| The Efficacy of Lung and Kidney Supplementation Formula on the Pulmonary Rehabilitation of Stable Patients with Chronic Obstructive Pulmonary Disease |
| DOI：10.16466/j.issn1005-5509.2025.02.009 |
| 中文关键词: 慢性阻塞性肺疾病 肺肾气虚 补肺益肾方 肺功能 慢性阻塞性肺疾病评估测试 咳嗽能力 体质量指数 肺康复 |
| 英文关键词: chronic obstructive pulmonary disease deficiency of lung and kidney Qi Lung and Kidney Supplementation Formula pulmonary function chronic obstructive pulmonary disease assessment test cough ability body mass index pulmonary rehabilitation |
| 基金项目:浙江省中医药科技计划项目(2022ZA003) |
|
| 摘要点击次数: 75 |
| 全文下载次数: 68 |
| 中文摘要: |
| [目的] 观察补肺益肾方对肺肾气虚型慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)稳定期患者肺康复的作用。[方法] 搜集2021年10月至2023年1月浙江医院确诊的肺肾气虚型COPD稳定期患者55例，随机分成试验组(26例)和对照组(29例)。对照组予稳定期吸入剂+肺康复运动训练治疗方案，试验组在此基础上予补肺益肾方加减治疗。评估两组患者治疗前，治疗第4周、第8周的肺功能指标第 1秒用力呼气容积(forced expiratory volume in the first second，FEV1)、第 1秒用力呼气容积占预计值百分比(forced expiratory volume in the first second to predicted values，FEV1%)、第一秒用力呼气容积占用力肺活量比值(forced expiratory volume in one second to forced vital capacity，FEV1/FVC)、慢性阻塞性肺疾病评估测试(chronic obstructive pulmonary disease assessment test，CAT) 评分、咳嗽能力评分、咳痰难度评分、体质量指数(body mass index，BMI)，并监测患者不良反应情况。[结果] 与本组治疗前比较，两组在治疗4周、8周，FEV1、FEV1%均有升高，CAT评分、咳嗽难度均有下降，差异均有统计学意义(P<0.05)；BMI、咳嗽能力差异无统计学意义(P>0.05)；试验组FEV1/FVC治疗4周差异无统计学意义(P>0.05)，治疗8周升高，差异有统计学意义(P<0.05)。与对照组同期比较，试验组在治疗4周、8周， CAT评分降低、咳嗽难度下降，差异均有统计学意义(P<0.05)，FEV1、FEV1%、咳嗽能力、BMI差异均无统计学意义(P>0.05)；试验组FEV1/FVC在治疗4周差异无统计学意义(P>0.05)，治疗8周升高，差异有统计学意义(P<0.05)。[结论] 补肺益肾方在COPD稳定期患者中对肺康复起到协同作用。 |
| 英文摘要: |
| [Objective] To observe the effect of Lung and Kidney Supplementation Formula on pulmonary rehabilitation in COPD patients with lung and kidney deficiency during the stable period. [Methods] A total of fifty-five stable COPD patients meeting the criteria of lung and kidney Qi deficiency diagnosed in Zhejiang Hospital from October 2021 to January 2023 were randomly allocated into either the experimental group (26 patients) or the control group (29 patients).The treatment of control group had regular inhalation and pulmonary rehabilitation exercise training， while the experimental group took Lung and Kidney Supplementation Formula on the base above. Pulmonary function indexes (FEV1， FEV1%， FEV1/FVC)， CAT score， cough ability score， cough difficulty ability score， BMI and TCM evidence score were evaluated in the two groups respectively before treatment， at 4 weeks and 8 weeks of treatment， and adverse reactions were monitored. [Results] In comparison to the baseline， both groups showed an increase in FEV1 and FEV1% at 4 weeks and 8 weeks of treatment， a decrease in CAT score and cough difficulty， with statistically significant differences (P<0.05); BMI and cough ability showed no statistically significant differences (P>0.05); there was no statistically significant difference in FEV1/FVC between the treatment groups at 4 weeks (P > 0.05)， but an increase at 8 weeks， with statistically significant differences (P<0.05). In comparison to the control group， the experimental group demonstrated a notable reduction in CAT scores and cough difficulty at both 4 weeks and 8 weeks of treatment， indicating statistically significant differences (P<0.05); however， no statistically significant differences were observed in FEV1， FEV1%， cough ability or BMI (P>0.05);the experimental group demonstrated a significant increase in FEV1/FVC at 8 weeks of treatment (P<0.05)，however，no statistically significant differences was indicated in FEV1/FVC at 4 weeks of treatment (P>0.05). [Conclusion] The Lung and Kidney Supplementation Formula exhibits a synergistic impact on pulmonary rehabilitation in individuals with COPD. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |